April 10, 2025
TOPLINE: Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) reduces the risk for disease progression, relapse, or death by 37% vs standard therapy in patients […]
April 10, 2025
TOPLINE: A review of the distribution of risk estimates from three commonly used genomic assays for breast cancer found that Black women were more likely to […]
April 10, 2025
ATHENS, Greece — Two strategies under investigation suggest that manipulating the gut microbiome could improve the effectiveness of immunotherapy in patients with melanoma, according to new […]
April 10, 2025
TOPLINE: A study found that among US adults eligible for lung cancer screening (LCS), the uptake of colorectal cancer (CRC) and breast cancer screening was nearly […]
April 10, 2025
Cancer statistics in Europe are encouraging: Between 1989 and 2025, nearly 7 million deaths were averted in the European Union (EU), including over 373,000 from breast […]
April 9, 2025
Immune checkpoint (IC) inhibitor drug holidays are safe in patients with metastatic melanoma who achieve an objective response (OR) during therapy, according to a study of […]
April 9, 2025
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and […]
April 9, 2025
ATHENS, Greece — Real-world data confirm that complete nodal dissection following a positive sentinel lymph node biopsy in patients with stage III melanoma and micrometastases does […]
April 9, 2025
ATHENS, Greece — According to the Global Cancer Observatory and the World Health Organization, over 300,000 new cases of invasive melanoma were diagnosed worldwide in 2022. […]